John is Executive Director, Vice President, Worldwide Business Development at Pfizer. In addition to leading oncology business development, John also has corporate business development responsibilities. John leads a team that provides search and evaluation and transaction support for oncology. John joined Pfizer in 1991 in U.S. Pharmaceutical Finance. After three years in Finance, John joined the U.S. Marketing organization supporting Norvasc, Procardia XL, and New Product Development (NPD). In 1997, John became the U.S. Team Leader of NPD and in 2000 his role was expanded to Group Leader of Worldwide Pharmaceuticals. In 2006, John joined Worldwide Business Development. John is a member of the Oncology Leadership Team and Worldwide Business Development Leadership Team. John has led a vast array of transformational deals at Pfizer, including M&A deals such as Medivation and Array, to evolving deals like Trillium, to more recent partnerships like Arvinas and Myovant. In both 2023 and 2024, John participated in panels at BIO International exploring how to strike a deal in Oncology. John received his bachelor’s degree in Business from Michigan State University in 1985 and his MBA from the University of Chicago in 1990.